Literature DB >> 2941293

Ciprofloxacin in the treatment of infections caused by gentamicin-resistant gram-negative bacteria.

S Mehtar, Y Drabu, P Blakemore.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2941293     DOI： 10.1007/bf02014001

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN： 0722-2211            Impact factor:   3.267


× No keyword cloud information.
  3 in total

1.  Multiply resistant Salmonella typhimurium septicaemia in an immunocompromised patient successfully treated with ciprofloxacin.

Authors:  W N Patton; G M Smith; M J Leyland; A M Geddes
Journal:  J Antimicrob Chemother       Date:  1985-11       Impact factor: 5.790

2.  Mutational resistance to 4-quinolone antibacterial agents.

Authors:  J T Smith
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

3.  The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.

Authors:  A King; K Shannon; I Phillips
Journal:  J Antimicrob Chemother       Date:  1985-05       Impact factor: 5.790
  3 in total
  10 in total

Review 1.  Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 2.  Overview of clinical experience with ciprofloxacin.

Authors:  A P Ball
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

3.  Analysis of acquired ciprofloxacin resistance in a clinical strain of Pseudomonas aeruginosa.

Authors:  B L Masecar; R A Celesk; N J Robillard
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

4.  Comparative efficacy of ciprofloxacin, azlocillin, imipenem/cilastatin and tobramycin in a model of experimental septicemia due to Pseudomonas aeruginosa in neutropenic mice.

Authors:  E Ulrich; M Trautmann; B Krause; A Bauernfeind; H Hahn
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

5.  Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.

Authors:  J Fung-Tomc; B Kolek; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

7.  Use of a broad-host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant gram-negative bacteria.

Authors:  P Heisig; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

8.  Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

Review 9.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.